Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Harbour BioMed Out-Licenses US Rights for Bispecific in $588 Million Deal

publication date: Feb 15, 2023

Harbour BioMed out-licensed US rights for a bispecific immune activator to Cullinan Oncology of Alabama in a $588 million deal. Harbour created HBM7008, a B7H4 x 4-1BB bispecific, using its next-gen heavy chain only multi-specific antibody discovery platform, HBICE®. The company will receive $25 million upfront, $148 million in development/regulatory milestones, up to $415 million in sales milestones, plus tiered royalties. Harbour is conducting US and Australian Phase I trials of HBM7008 in patients with advanced solid tumors. Harbour has development labs in China, Boston headquarters and drug discovery operations in Rotterdam. More details....

Stock Symbols: (HK: 02142) (NSDQ: CGEM)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital